Christopher U. Missling PhD, MBA

Christopher U. Missling, Ph.D. is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for rare diseases especially for neurodevelopmental diseases, like Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms as well as neurodegenerative diseases.

Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and Ph.D. from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.